Helen  Sabzevari net worth and biography

Helen Sabzevari Biography and Net Worth

CEO of Precigen
Dr. Helen Sabzevari is President and CEO of Precigen and member of the Precigen Board of Directors. Dr. Sabzevari brings extensive expertise in research and development of immunotherapy-based therapeutics as well as experience translating novel treatments from pre-clinical stage into the clinic. From 2015 to 2017, Dr. Sabzevari co-founded and served as Chief Scientific Officer of Compass Therapeutics, a fully-integrated drug discovery and development company focused on manipulating the immune system to treat human disease. From 2008 to 2014, Dr. Sabzevari served as Senior Vice President of Immuno-Oncology as well as Global Head of Immunotherapy, Oncology, Global Research and Early Development at EMD Serono (a subsidiary of Merck KGaA, Darmstadt, Germany). During her tenure, she led the immuno-oncology discovery and early development translational innovation platform and brought forward numerous pre-clinical and clinical assets including avelumab, an approved anti-programmed death ligand-1 (PD-L1) checkpoint inhibitor. From 1998 to 2008, Dr. Sabzevari led the Molecular Immunology Group at the Laboratory of Tumor Immunology and Biology at the US National Cancer Institute (LTIB-NCI), where she was focused on design, development and delivery of novel vaccines and immunotherapies for a range of human cancers. Dr. Sabzevari’s contributions in the field of tumor immunology earned her the National Institutes of Health (NIH) merit award for major contribution to the field of cancer immunotherapy, and she has also received the Mass High Tech’s Women to Watch Award and the PharmaVOICE 100 Award. Most recently, Dr. Sabzevari received the Society for Immunotherapy of Cancer (SITC) Team Science Award for her work on the NCI Cancer Immunotherapy Program Team. Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the department of immunology at the Scripps Research Institute working on various immunotherapeutic modalities in the treatment of cancer and autoimmune diseases.

What is Helen Sabzevari's net worth?

The estimated net worth of Helen Sabzevari is at least $1.90 million as of August 25th, 2023. Dr. Sabzevari owns 1,560,004 shares of Precigen stock worth more than $1,895,405 as of December 6th. This net worth approximation does not reflect any other assets that Dr. Sabzevari may own. Additionally, Dr. Sabzevari receives a salary of $1,290,000.00 as CEO at Precigen. Learn More about Helen Sabzevari's net worth.

How old is Helen Sabzevari?

Dr. Sabzevari is currently 61 years old. There are 6 older executives and no younger executives at Precigen. Learn More on Helen Sabzevari's age.

What is Helen Sabzevari's salary?

As the CEO of Precigen, Inc., Dr. Sabzevari earns $1,290,000.00 per year. Learn More on Helen Sabzevari's salary.

How do I contact Helen Sabzevari?

The corporate mailing address for Dr. Sabzevari and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Helen Sabzevari's contact information.

Has Helen Sabzevari been buying or selling shares of Precigen?

Helen Sabzevari has not been actively trading shares of Precigen during the last quarter. Most recently, Helen Sabzevari sold 76,969 shares of the business's stock in a transaction on Friday, August 25th. The shares were sold at an average price of $1.53, for a transaction totalling $117,762.57. Following the completion of the sale, the chief executive officer now directly owns 1,560,004 shares of the company's stock, valued at $2,386,806.12. Learn More on Helen Sabzevari's trading history.

Who are Precigen's active insiders?

Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.

Are insiders buying or selling shares of Precigen?

In the last year, Precigen insiders bought shares 7 times. They purchased a total of 12,033,552 shares worth more than $21,009,557.36. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 359,020 shares worth more than $513,769.48. The most recent insider tranaction occured on September, 22nd when Director Dean J Mitchell bought 25,000 shares worth more than $35,250.00. Insiders at Precigen own 41.7% of the company. Learn More about insider trades at Precigen.

Information on this page was last updated on 9/22/2023.

Helen Sabzevari Insider Trading History at Precigen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2023Sell76,969$1.53$117,762.571,560,004View SEC Filing Icon  
8/18/2023Sell55,855$1.66$92,719.301,495,386View SEC Filing Icon  
8/11/2023Sell41,436$1.44$59,667.841,409,654View SEC Filing Icon  
8/4/2023Sell52,870$1.10$58,157.001,309,503View SEC Filing Icon  
1/27/2023Buy22,857$1.75$39,999.75937,613View SEC Filing Icon  
5/13/2022Sell177,968$1.19$211,781.92897,091View SEC Filing Icon  
1/5/2022Sell6,960$3.59$24,986.40View SEC Filing Icon  
1/3/2022Sell3,848$3.67$14,122.16View SEC Filing Icon  
7/19/2021Sell12,531$5.43$68,043.33View SEC Filing Icon  
5/13/2021Sell47,433$6.40$303,571.20752,490View SEC Filing Icon  
1/5/2021Sell9,040$10.56$95,462.40424,299View SEC Filing Icon  
7/20/2020Sell12,220$4.58$55,967.60414,365View SEC Filing Icon  
1/6/2020Sell6,732$5.83$39,247.56104,734View SEC Filing Icon  
1/3/2020Sell3,886$5.77$22,422.2290,953View SEC Filing Icon  
7/18/2019Sell8,484$7.47$63,375.4870,825View SEC Filing Icon  
7/18/2018Sell8,402$14.54$122,165.0825,000View SEC Filing Icon  
See Full Table

Helen Sabzevari Buying and Selling Activity at Precigen

This chart shows Helen Sabzevari's buying and selling at Precigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Precigen Company Overview

Precigen logo
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More

Today's Range

Now: $1.22
Low: $1.20
High: $1.27

50 Day Range

MA: $1.17
Low: $0.89
High: $1.43

2 Week Range

Now: $1.22
Low: $0.81
High: $2.29


940,677 shs

Average Volume

1,643,673 shs

Market Capitalization

$302.44 million

P/E Ratio


Dividend Yield